Triastek
Latest round
- Series B
Last raised
- Nov 2021
Total raised
- $82M
Investors
- 9
About Triastek
, trading as Triastek, operates as a 3D printing pharmaceutical professional company that provides 3D printing drug development and equipment.S. FDA's emerging technology project and its products cover China, the United States, Europe, Canada, and Australia, etc. It is headquartered in Nanjing and has a branch in Shanghai. In March 2023, Bollinger Ingelheim China became the partner of the company. In June 2023, the company was awarded as the "2023 TCT Awards' Best Medical Application Award". In July 2026, it closed a strategic investment. The company develops (MED) melt extrusion deposition, semi-solid extrusion, micro injection molding and micro-droplet injection technologies. Its product lines cover T19 rheumatoid arthritis, T20 cardiovascular disease and T21 ulcerative colitis, etc. The company has many clients, such as Lilly, Bollinger Ingelheim, Merck, Siemens and Shufang. The company generates revenue from proprietary drug product development, pharmaceutical technology licensing, drug formulation development services and other related services.
Who invested in Triastek
9 investors across 4 rounds
See all investors in Triastek
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Triastek
Who invested in Triastek?
Triastek has 9 investors on record across 4 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Triastek raised?
Triastek has raised 4 venture rounds. Sign up free to see how much each round raised and the total.
When did Triastek last raise money?
Triastek's most recent round on record is a Series B, in Nov 2021.
What does Triastek do?
, trading as Triastek, operates as a 3D printing pharmaceutical professional company that provides 3D printing drug development and equipment.
Where is Triastek headquartered?
Triastek is headquartered in Nanjing, China.
Which VCs invest in companies like Triastek?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Yufu Capital, ICBC Capital Management and Ningbo Tongshang Fund back pharmaceuticals companies at Triastek's stage. Their profiles are linked below.
VCs backing pharmaceuticals startups at Series B
Raising like Triastek? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.